The goal of this observational study is to evaluate how well advanced therapies work in adults with psoriatic arthritis (PsA) who are starting a biologic or targeted synthetic disease-modifying antirheumatic drug (b/tsDMARD) as part of routine care.
The main questions are:
* Do treatment responses differ according to the number of previous advanced therapies? * Can anti-drug antibodies (ADAs) or blood drug levels help predict treatment effectiveness?
Researchers will compare participants receiving earlier-line versus later-line advanced therapies to assess differences in treatment response and antibody development.
Participants will allow collection of routine clinical assessment data, complete questionnaires on symptoms and quality of life, and provide blood samples before treatment and at 12 weeks.
Age ≥18 years
Clinical diagnosis of PsA meeting CASPAR criteria
Starting a new b/tsDMARD, irrespective of line of therapy
Switching b/tsDMARD therapy for psoriasis or spondyloarthritis alone, without active psoriatic arthritis.
Previous treatment with the same b/tsDMARD being started at baseline.
Inability or unwillingness to provide informed consent.
Royal United Hospitals Bath NHS Foundation Trust
Lead sponsor
University of Bath
Collaborator